{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:00:23Z","timestamp":1774026023465,"version":"3.50.1"},"reference-count":174,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Blockade of immune checkpoints transformed the paradigm of systemic cancer therapy, enabling substitution of a cytotoxic chemotherapy backbone to one of immunostimulation in many settings. Invigorating host immune cells against tumor neo-antigens, however, can induce severe autoimmune toxicity which in many cases requires ongoing management. Many immune-related adverse events (irAEs) are clinically and pathologically indistinguishable from inborn errors of immunity arising from genetic polymorphisms of immune checkpoint genes, suggesting a possible shared driver for both conditions. Many endocrine irAEs, for example, have analogous primary genetic conditions with varied penetrance and severity despite consistent genetic change. This is akin to onset of irAEs in response to immune checkpoint inhibitors (ICIs), which vary in timing, severity and nature despite a consistent drug target. Host contribution to ICI response and irAEs, particularly those of endocrine origin, such as thyroiditis, hypophysitis, adrenalitis and diabetes mellitus, remains poorly defined. Improved understanding of host factors contributing to ICI outcomes is essential for tailoring care to an individual\u2019s unique genetic predisposition to response and toxicity, and are discussed in detail in this review.<\/jats:p>","DOI":"10.3389\/fonc.2022.894015","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T05:16:31Z","timestamp":1657775791000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Adrian","family":"Chye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"India","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Barnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah L.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/bies.201800050","article-title":"Understanding Immune Tolerance of Cancer: Re-Purposing Insights From Fetal Allografts and Microbes","volume":"40","author":"Barnet","year":"2018","journal-title":"Bioessays"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0342","article-title":"Management of Endocrine Immune-Related Adverse Events of Immune Checkpoint Inhibitors: An Updated Review","volume":"9","author":"Stelmachowska-Bana\u015b","year":"2020","journal-title":"Endocr Connect"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.633032","article-title":"Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-Analysis","volume":"11","author":"Fan","year":"2021","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.357","article-title":"The Positive Effect of Immune Checkpoint Inhibitor-Induced Thyroiditis on Overall Survival Accounting for Immortal Time Bias: A Retrospective Cohort Study of 6596 Patients","volume":"32","author":"Street","year":"2021","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early Immune-Related Adverse Events and Association With Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab: A Prospective Cohort Study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1922867117","article-title":"Polygenic Risk for Skin Autoimmunity Impacts Immune Checkpoint Blockade in Bladder Cancer","volume":"117","author":"Khan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.806043","article-title":"Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1","volume":"12","author":"Hao","year":"2021","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3746","article-title":"Autosomal Dominant Immune Dysregulation Syndrome in Humans With CTLA4 Mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, Penetrance, and Treatment of 133 Cytotoxic T-Lymphocyte Antigen 4-Insufficient Subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1055\/a-0843-3366","article-title":"A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated With Immune Checkpoint Inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival With Ipilimumab in Patients With Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant Ipilimumab Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (EORTC 18071): A Randomised, Double-Blind, Phase 3 Trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 Mg\/Kg Versus Ipilimumab 3 Mg\/Kg in Patients With Unresectable or Metastatic Melanoma: A Randomised, Double-Blind, Multicentre, Phase 3 Trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01388-5","article-title":"Inherited PD-1 Deficiency Underlies Tuberculosis and Autoimmunity in a Child","volume":"27","author":"Ogishi","year":"2021","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"New Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab Versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"New Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab Versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cell.2007.06.033","article-title":"Multistep Pathogenesis of Autoimmune Disease","volume":"130","author":"Goodnow","year":"2007","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cell.2020.01.029","article-title":"Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody","volume":"180","author":"Singh","year":"2020","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf3041","article-title":"Single-Cell eQTL Mapping Identifies Cell Type-Specific Genetic Control of Autoimmune Disease","volume":"376","author":"Yazar","year":"2022","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf1970","article-title":"Single-Cell RNA-Seq Reveals Cell Type-Specific Molecular and Genetic Associations to Lupus","volume":"376","author":"Perez","year":"2022","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"a006957","DOI":"10.1101\/cshperspect.a006957","article-title":"T-Cell Tolerance: Central and Peripheral","volume":"4","author":"Xing","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03547.x","article-title":"T-Cell Receptor Affinity in Thymic Development","volume":"135","author":"Moran","year":"2012","journal-title":"Immunology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/79790","article-title":"Receptor Editing in Developing T Cells","volume":"1","author":"McGargill","year":"2000","journal-title":"Nat Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00080-7","article-title":"Impact of Negative Selection on the T Cell Repertoire Reactive to a Self-Peptide: A Large Fraction of T Cell Clones Escapes Clonal Deletion","volume":"13","author":"Bouneaud","year":"2000","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00454-2","article-title":"Rethinking Peripheral T Cell Tolerance: Checkpoints Across a T Cell\u2019s Journey","volume":"21","author":"ElTanbouly","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1600-065X.2010.00911.x","article-title":"The Metabolic Life and Times of a T-Cell","volume":"236","author":"Michalek","year":"2010","journal-title":"Immunol Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.icb.7100161","article-title":"Too Dangerous to Ignore: Self-Tolerance and the Control of Ignorant Autoreactive T Cells","volume":"86","author":"Parish","year":"2008","journal-title":"Immunol Cell Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.immuni.2015.10.011","article-title":"CD4+ T Cell Tolerance to Tissue-Restricted Self Antigens Is Mediated by Antigen-Specific Regulatory T Cells Rather Than Deletion","volume":"43","author":"Legoux","year":"2015","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3327","article-title":"Tolerance is Established in Polyclonal CD4(+) T Cells by Distinct Mechanisms, According to Self-Peptide Expression Patterns","volume":"17","author":"Malhotra","year":"2016","journal-title":"Nat Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/s0140-6736(00)05185-0","article-title":"Pathways for Self-Tolerance and the Treatment of Autoimmune Diseases","volume":"2001","author":"Goodnow","year":"9274","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.immunol.14.1.1","article-title":"Altered Peptide Ligand-Induced Partial T Cell Activation: Molecular Mechanisms and Role in T Cell Biology","volume":"14","author":"Sloan-Lancaster","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.157.5.1434","article-title":"Induction of Tolerance in Influenza Virus-Immune T Lymphocyte Clones With Synthetic Peptides of Influenza Hemagglutinin","volume":"157","author":"Lamb","year":"1983","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035","article-title":"T Cell Exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2233","article-title":"Cellular Senescence: When Bad Things Happen to Good Cells","volume":"8","author":"Campisi","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.4049\/jimmunol.174.7.4098","article-title":"Peripheral Deletion of Antigen-Specific T Cells Leads to Long-Term Tolerance Mediated by CD8+ Cytotoxic Cells","volume":"174","author":"Herndon","year":"2005","journal-title":"J Immunol"},{"key":"B38","volume-title":"The Clonal Selection Theory of Acquired Immunity ; the Abraham Flexner Lectures of Vanderbilt University","author":"Burnet","year":"1959"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.19","article-title":"Mechanisms of Central Tolerance for B Cells","volume":"17","author":"Nemazee","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/337562a0","article-title":"Clonal Deletion of B Lymphocytes in a Transgenic Mouse Bearing Anti-MHC Class I Antibody Genes","volume":"337","author":"Nemazee","year":"1989","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","first-page":"418","DOI":"10.4049\/jimmunol.1900175","article-title":"Optimal Development of Mature B Cells Requires Recognition of Endogenous Antigens","volume":"203","author":"Noviski","year":"2019","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/342385a0","article-title":"Induction of Self-Tolerance in Mature Peripheral B Lymphocytes","volume":"342","author":"Goodnow","year":"1989","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.10.017","article-title":"Identification of Anergic B Cells Within a Wild-Type Repertoire","volume":"25","author":"Merrell","year":"2006","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042251","article-title":"Defective B Cell Tolerance Checkpoints in Systemic Lupus Erythematosus","volume":"201","author":"Yurasov","year":"2005","journal-title":"J Exp Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/334676a0","article-title":"Altered Immunoglobulin Expression and Functional Silencing of Self-Reactive B Lymphocytes in Transgenic Mice","volume":"334","author":"Goodnow","year":"1988","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/imr.12808","article-title":"Clonal Redemption and Clonal Anergy as Mechanisms to Balance B Cell Tolerance and Immunity","volume":"292","author":"Burnett","year":"2019","journal-title":"Immunol Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202115","article-title":"TLR9 Promotes Tolerance by Restricting Survival of Anergic Anti-DNA B Cells, Yet Is Also Required for Their Activation","volume":"190","author":"Nickerson","year":"2013","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3859","article-title":"Germinal Center Antibody Mutation Trajectories Are Determined by Rapid Self\/Foreign Discrimination","volume":"360","author":"Burnett","year":"2018","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005102117","article-title":"Conformational Diversity Facilitates Antibody Mutation Trajectories and Discrimination Between Foreign and Self-Antigens","author":"Burnett","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005102117","article-title":"Redemption of Autoantibodies on Anergic B Cells by Variable-Region Glycosylation and Mutation Away From Self-Reactivity","volume":"1110","author":"Sabouri","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.3.1178","article-title":"Induction of Antigen-Specific T Cell Anergy: An Early Event in the Course of Tumor Progression","volume":"95","author":"Staveley-O'Carroll","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B53","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T Cells, Tumour Immunity and Immunotherapy","volume":"6","author":"Zou","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0635","article-title":"Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity","volume":"20","author":"Mao","year":"2014","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.01.004","article-title":"The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1096","article-title":"Production of Vascular Endothelial Growth Factor by Human Tumors Inhibits the Functional Maturation of Dendritic Cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.07.001","article-title":"TGFbeta in Cancer","volume":"134","author":"Massagu\u00e9","year":"2008","journal-title":"Cell"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK Cells Stimulate Recruitment of Cdc1 Into the Tumor Microenvironment Promoting Cancer Immune Control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000475","article-title":"Dendritic Cell-Specific ICAM-3\u2013Grabbing Nonintegrin Expression on M2-Polarized and Tumor-Associated Macrophages Is Macrophage-CSF Dependent and Enhanced by Tumor-Derived IL-6 and IL-10","volume":"186","author":"Dom\u00ednguez-Soto","year":"2011","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.163.7.3718","article-title":"Tumor Gangliosides Inhibit the Tumor-Specific Immune Response","volume":"163","author":"McKallip","year":"1999","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00771.x","article-title":"Costimulatory and Coinhibitory Receptors in Anti-Tumor Immunity","volume":"229","author":"Driessens","year":"2009","journal-title":"Immunol Rev"},{"key":"B62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/imcb.1003","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy: A Focus on T-Regulatory Cells","volume":"96","author":"Sasidharan Nair","year":"2018","journal-title":"Immunol Cell Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nri1131","article-title":"Unifying Concepts in CD28, ICOS and CTLA4 Co-Receptor Signalling","volume":"3","author":"Rudd","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00242.x","article-title":"The B7\/CD28 Costimulatory Family in Autoimmunity","volume":"204","author":"Keir","year":"2005","journal-title":"Immunol Rev"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/science.1202947","article-title":"Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","article-title":"Human B7-1 (CD80) and B7-2 (CD86) Bind With Similar Avidities But Distinct Kinetics to CD28 and CTLA-4 Receptors","volume":"1","author":"Linsley","year":"1994","journal-title":"Immunity"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.6.2049","article-title":"Complementarity Determining Region 1 (CDR1)- and CDR3-Analogous Regions in CTLA-4 and CD28 Determine the Binding to B7-1","volume":"180","author":"Peach","year":"1994","journal-title":"J Exp Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.1.144","article-title":"CD28 Costimulation Mediates T Cell Expansion via IL-2-Independent and IL-2-Dependent Regulation of Cell Cycle Progression","volume":"164","author":"Appleman","year":"2000","journal-title":"J Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor Antigen-Specific CD8 T Cells Infiltrating the Tumor Express High Levels of PD-1 and are Functionally Impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The Blockade of Immune Checkpoints in Cancer Immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety Profiles of Anti-CTLA-4 and Anti-PD-1 Antibodies Alone and in Combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"14039","DOI":"10.1038\/s41598-019-50574-6","article-title":"Risk Factors for Immune-Related Adverse Events Associated With Anti-PD-1 Pembrolizumab","volume":"9","author":"Eun","year":"2019","journal-title":"Sci Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23217","article-title":"Relationships Between Lymphocyte Counts and Treatment-Related Toxicities and Clinical Responses in Patients With Solid Tumors Treated With PD-1 Checkpoint Inhibitors","volume":"8","author":"Diehl","year":"2017","journal-title":"Oncotarget"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.03.020","article-title":"Predictive Value of Serum Protein Levels in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab","volume":"132","author":"Oyanagi","year":"2019","journal-title":"Lung Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-Mediated Thyroid Dysfunction During T-Cell Checkpoint Blockade in Patients With non-Small-Cell Lung Cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00845-w","article-title":"Germinal Immunogenetics Predict Treatment Outcome for PD-1\/PD-L1 Checkpoint Inhibitors","volume":"38","author":"Refae","year":"2020","journal-title":"Investigat New Drugs"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0074-1","article-title":"Association Between Single-Nucleotide Polymorphisms and Adverse Events in Nivolumab-Treated Non-Small Cell Lung Cancer Patients","volume":"118","author":"Bins","year":"2018","journal-title":"Br J Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal Microbiome Analyses Identify Melanoma Patients at Risk for Checkpoint-Blockade-Induced Colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline Gut Microbiota Predicts Clinical Response and Colitis in Metastatic Melanoma Patients Treated With Ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed Immune-Related Adverse Events With Anti-PD-1-Based Immunotherapy in Melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse Effects of Immune-Checkpoint Inhibitors: Epidemiology, Management and Surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive Meta-Analysis of Key Immune-Related Adverse Events From CTLA-4 and PD-1\/PD-L1 Inhibitors in Cancer Patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.06.019","article-title":"Human Beta Cell Mass and Function in Diabetes: Recent Advances in Knowledge and Technologies to Understand Disease Pathogenesis","volume":"6","author":"Chen","year":"2017","journal-title":"Mol Metab"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1210\/er.2013-1055","article-title":"Breaking Tolerance to Thyroid Antigens: Changing Concepts in Thyroid Autoimmunity","volume":"35","author":"McLachlan","year":"2014","journal-title":"Endocrine Rev"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb7495","article-title":"CD4+ T Cells are Essential for the Development of Destructive Thyroiditis Induced by Anti\u2013PD-1 Antibody in Thyroglobulin-Immunized Mice","volume":"13","author":"Yasuda","year":"2021","journal-title":"Sci Trans Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"102285","DOI":"10.1016\/j.jaut.2019.05.013","article-title":"Analysis of the PD-1\/PD-L1 Axis in Human Autoimmune Thyroid Disease: Insights Into Pathogenesis and Clues to Immunotherapy Associated Thyroid Autoimmunity","volume":"103","author":"\u00c1lvarez-Sierra","year":"2019","journal-title":"J Autoimmun"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00432","article-title":"Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13800","article-title":"Association of Antithyroglobulin Antibodies With the Development of Thyroid Dysfunction Induced by Nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci"},{"key":"B96","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1038\/s41467-021-23661-4","article-title":"Genetic Variation Associated With Thyroid Autoimmunity Shapes the Systemic Immune Response to PD-1 Checkpoint Blockade","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01058-x","article-title":"Low Frequency of Positive Antithyroid Antibodies is Observed in Patients With Thyroid Dysfunction Related to Immune Check Point Inhibitors","volume":"42","author":"Mazarico","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0513","article-title":"Immune Checkpoint Inhibitor Related Hypophysitis: Diagnostic Criteria and Recovery Patterns","volume":"28","author":"Nguyen","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis Secondary to Nivolumab and Pembrolizumab Is a Clinical Entity Distinct From Ipilimumab-Associated Hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B101","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1479-5876-11-108","article-title":"The Engagement of CTLA-4 on Primary Melanoma Cell Lines Induces Antibody-Dependent Cellular Cytotoxicity and TNF-\u03b1 Production","volume":"11","author":"Laurent","year":"2013","journal-title":"J Transl Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and Hypophysitis: Clinical Presentation, Treatment, and Biologic Insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights Into Pathogenesis From an Autopsy Series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13424","article-title":"Immune Checkpoint Inhibitor Diabetes Mellitus: A Novel Form of Autoimmune Diabetes","volume":"200","author":"Quandt","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0291","article-title":"Immune Checkpoint Inhibitors and Type 1 Diabetes Mellitus: A Case Report and Systematic Review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1465","article-title":"Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2518","article-title":"T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"key":"B110","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/jc.2009-1365","article-title":"Clinical Applications of Diabetes Antibody Testing","volume":"95","author":"Bingley","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B111","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2020.09.016","article-title":"Immune Checkpoint Inhibitor-Induced Adrenalitis and Primary Adrenal Insufficiency: Systematic Review and Optimal Management","volume":"27","author":"Shi","year":"2021","journal-title":"Endocr Pract"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J Endocr Soc"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.04.001","article-title":"Immunotherapy-Induced Addison's Disease: A Rare, Persistent and Potentially Lethal Side-Effect","volume":"97","author":"Hescot","year":"2018","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.5.8626850","article-title":"Autoantibodies to Steroidogenic Enzymes in Autoimmune Polyglandular Syndrome, Addison's Disease, and Premature Ovarian Failure","volume":"81","author":"Chen","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/nature01621","article-title":"Association of the T-Cell Regulatory Gene CTLA4 With Susceptibility to Autoimmune Disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative Disorders With Early Lethality in Mice Deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 Leads to Massive Lymphoproliferation and Fatal Multiorgan Tissue Destruction, Revealing a Critical Negative Regulatory Role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1126\/science.1255904","article-title":"Immune Dysregulation in Human Subjects With Heterozygous Germline Mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20141030","article-title":"Deletion of CTLA-4 on Regulatory T Cells During Adulthood Leads to Resistance to Autoimmunity","volume":"212","author":"Paterson","year":"2015","journal-title":"J Exp Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab Monotherapy in Patients With Pretreated Advanced Melanoma: A Randomised, Double-Blind, Multicentre, Phase 2, Dose-Ranging Study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1663","article-title":"AUTOIMMUNE DISEASE. Patients With LRBA Deficiency Show CTLA4 Loss and Immune Dysregulation Responsive to Abatacept Therapy","volume":"349","author":"Lo","year":"2015","journal-title":"Science"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1046\/j.1399-0039.2003.00136.x","article-title":"Association of a Putative Regulatory Polymorphism in the PD-1 Gene With Susceptibility to Type 1 Diabetes","volume":"62","author":"Nielsen","year":"2003","journal-title":"Tissue Antigens"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201767","article-title":"Association of PDCD1 Polymorphisms With Childhood-Onset Systemic Lupus Erythematosus","volume":"15","author":"Vel\u00e1zquez-Cruz","year":"2007","journal-title":"Eur J Hum Genet"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.05.003","article-title":"Recent Insights Into the Role of the PD-1\/PD-L1 Pathway in Immunological Tolerance and Autoimmunity","volume":"12","author":"Gianchecchi","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.10.1563","article-title":"Immunological Studies on PD-1 Deficient Mice: Implication of PD-1 as a Negative Regulator for B Cell Responses","volume":"10","author":"Nishimura","year":"1998","journal-title":"Int Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of Lupus-Like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0505497102","article-title":"Establishment of NOD-Pdcd1-\/- Mice as an Efficient Animal Model of Type I Diabetes","volume":"102","author":"Wang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31817fd8f3","article-title":"Influence of Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade","volume":"31","author":"Breunis","year":"2008","journal-title":"J Immunother"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2013.793699","article-title":"Association of CTLA-4 Polymorphisms With Improved Overall Survival in Melanoma Patients Treated With CTLA-4 Blockade: A Pilot Study","volume":"31","author":"Queirolo","year":"2013","journal-title":"Cancer Invest"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.2.180","article-title":"An Association Between the CTLA4 Exon 1 Polymorphism and Early Rheumatoid Arthritis With Autoimmune Endocrinopathies","volume":"41","author":"Vaidya","year":"2002","journal-title":"Rheumatol (Oxford)"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3892\/br.2015.493","article-title":"Association of the CTLA4 Gene CT60\/rs3087243 Single-Nucleotide Polymorphisms With Graves' Disease","volume":"3","author":"Fang","year":"2015","journal-title":"BioMed Rep"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6982623","article-title":"Correlation of TSHR and CTLA-4 Single Nucleotide Polymorphisms With Graves Disease","volume":"2019","author":"Sun","year":"2019","journal-title":"Int J Genomics"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111842","article-title":"Investigation of the Correlation Between Graves' Ophthalmopathy and CTLA4 Gene Polymorphism","volume":"8","author":"Chen","year":"2019","journal-title":"J Clin Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154394","article-title":"Association of Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4) Gene Polymorphisms With Autoimmune Thyroid Disease in Children and Adults: Case-Control Study","volume":"11","author":"Ting","year":"2016","journal-title":"PLoS One"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1407","article-title":"The Association of CTLA4 Polymorphism With Type 1 Diabetes is Concentrated in Patients Complicated With Autoimmune Thyroid Disease: A Multicenter Collaborative Study in Japan","volume":"91","author":"Ikegami","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02337-x","article-title":"Polymorphisms of the Genes CTLA4, PTPN22, CD40, and PPARG and Their Roles in Graves' Disease: Susceptibility and Clinical Features","volume":"71","author":"Bufalo","year":"2021","journal-title":"Endocrine"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2017.11.057","article-title":"Interaction of HLA-DRB1* Alleles and CTLA4 (+49 AG) Gene Polymorphism in Autoimmune Thyroid Disease","volume":"642","author":"Ramgopal","year":"2018","journal-title":"Gene"},{"key":"B141","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00439-005-0006-z","article-title":"CTLA4 is Differentially Associated With Autoimmune Diseases in the Dutch Population","volume":"118","author":"Zhernakova","year":"2005","journal-title":"Hum Genet"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-014-0162-x","article-title":"The Association of Cytotoxic T-Lymphocyte Antigen-4 + 49A\/G and CT60 Polymorphisms With Type 1 Diabetes and Latent Autoimmune Diabetes in Chinese Adults","volume":"38","author":"Jin","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-002-0807-2","article-title":"CTLA-4 Gene Polymorphisms in Systemic Lupus Erythematosus: A Highly Significant Association With a Determinant in the Promoter Region","volume":"111","author":"Hudson","year":"2002","journal-title":"Hum Genet"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/5.7.1075","article-title":"The CTLA-4 Gene Region of Chromosome 2q33 Is Linked to, and Associated With, Type 1 Diabetes. Belgian Diabetes Registry","volume":"5","author":"Nistic\u00f2","year":"1996","journal-title":"Hum Mol Genet"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1614683","DOI":"10.1155\/2018\/1614683","article-title":"Association of PD-1 and PD-L1 Genetic Polymorphyisms With Type 1 Diabetes Susceptibility","volume":"2018","author":"Qian","year":"2018","journal-title":"J Diabetes Res"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2015.27","article-title":"CTLA-4 as a Genetic Determinant in Autoimmune Addison's Disease","volume":"16","author":"Wolff","year":"2015","journal-title":"Genes Immunity"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0749.2004.00196.x","article-title":"CTLA4 Polymorphisms Are Associated With Vitiligo, in Patients With Concomitant Autoimmune Diseases","volume":"18","author":"Blomhoff","year":"2005","journal-title":"Pigment Cell Res"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2016.05.021","article-title":"Pemphigus Vulgaris and Pemphigus Foliaceus Determined by CD86 and CTLA4 Polymorphisms","volume":"35","author":"Tanasilovic","year":"2017","journal-title":"Clinics Dermatol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2009.03.016","article-title":"Influence of CTLA-4 Gene Polymorphism in Autoimmune and Infectious Diseases","volume":"70","author":"Fern\u00e1ndez-Mestre","year":"2009","journal-title":"Hum Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2010.04.001","article-title":"Polymorphisms in the 2q33 and 3q21 Chromosome Regions Including T-Cell Coreceptor and Ligand Genes may Influence Susceptibility to Pemphigus Foliaceus","volume":"71","author":"Dalla-Costa","year":"2010","journal-title":"Hum Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2013.05.014","article-title":"Association Between CTLA-4 Polymorphisms and Susceptibility to Celiac Disease: A Meta-Analysis","volume":"74","author":"Song","year":"2013","journal-title":"Hum Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.2.187","article-title":"CTLA-4 Gene Polymorphism Is Associated With Predisposition to Coeliac Disease","volume":"43","author":"Djilali-Saiah","year":"1998","journal-title":"Gut"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1086\/498651","article-title":"Replication of Putative Candidate-Gene Associations With Rheumatoid Arthritis in >4,000 Samples From North America and Sweden: Association of Susceptibility With PTPN22, CTLA4, and PADI4","volume":"77","author":"Plenge","year":"2005","journal-title":"Am J Hum Genet"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/ng1020","article-title":"A Regulatory Polymorphism in PDCD1 Is Associated With Susceptibility to Systemic Lupus Erythematosus in Humans","volume":"32","author":"Prokunina","year":"2002","journal-title":"Nat Genet"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1002\/art.20966","article-title":"A New Haplotype of PDCD1 Is Associated With Rheumatoid Arthritis in Hong Kong Chinese","volume":"52","author":"Kong","year":"2005","journal-title":"Arthritis Rheumatol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1002\/art.20040","article-title":"Association of a Programmed Death 1 Gene Polymorphism With the Development of Rheumatoid Arthritis, But Not Systemic Lupus Erythematosus","volume":"50","author":"Lin","year":"2004","journal-title":"Arthritis Rheumatol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2019.08.079","article-title":"Association Between CTLA-4 Gene Polymorphism and Myasthenia Gravis in a Chinese Cohort","volume":"69","author":"Cai","year":"2019","journal-title":"J Clin Neurosci"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101986","article-title":"CTLA4 Variants and Haplotype Contribute Genetic Susceptibility to Myasthenia Gravis in Northern Chinese Population","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(98)00119-2","article-title":"Genetic Association of Ctla-4 to Myasthenia Gravis With Thymoma","volume":"88","author":"Huang","year":"1998","journal-title":"J Neuroimmunol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1111\/j.1759-7714.2012.00121.x","article-title":"PTPN22 and CTLA-4 Gene Polymorphisms in Resected Thymomas and Thymus for Myasthenia Gravis","volume":"3","author":"Zheng","year":"2012","journal-title":"Thorac Cancer"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20577","article-title":"A CTLA4high Genotype Is Associated With Myasthenia Gravis in Thymoma Patients","volume":"58","author":"Chuang","year":"2005","journal-title":"Ann Neurol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-016-0024-y","article-title":"Gene Polymorphisms for Both Auto-Antigen and Immune-Modulating Proteins Are Associated With the Susceptibility of Autoimmune Myasthenia Gravis","volume":"54","author":"Li","year":"2017","journal-title":"Mol Neurobiol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6363816","article-title":"CDS1 and Promoter Single Nucleotide Polymorphisms of the CTLA-4 Gene in Human Myasthenia Gravis","volume":"3","author":"Wang","year":"2002","journal-title":"Genes Immun"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1002\/art.24227","article-title":"Genetic, Immunologic, and Immunohistochemical Analysis of the Programmed Death 1\/Programmed Death Ligand 1 Pathway in Human Systemic Lupus Erythematosus","volume":"60","author":"Bertsias","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1002\/art.22004","article-title":"Influence of CTLA4 Haplotypes on Susceptibility and Some Extraglandular Manifestations in Primary Sj\u00f6gren's Syndrome","volume":"54","author":"Downie-Doyle","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1111\/iji.12451","article-title":"Single-Nucleotide Polymorphisms Associated With Pemphigus Vulgaris: Potent Markers for Better Treatment and Personalized Medicine","volume":"47","author":"Mahmoudi","year":"2020","journal-title":"Int J Immunogenet"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0216-7","article-title":"Fine-Mapping and Functional Studies Highlight Potential Causal Variants for Rheumatoid Arthritis and Type 1 Diabetes","volume":"50","author":"Westra","year":"2018","journal-title":"Nat Genet"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1159\/000489953","article-title":"Association of Five Snps in Cytotoxic T-Lymphocyte Antigen 4 and Cancer Susceptibility: Evidence From 67 Studies","volume":"47","author":"Fang","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-013-1480-x","article-title":"Association Between Cytotoxic T Lymphocyte Antigen-4 +49A\/G, -1722t\/C, and -1661A\/G Polymorphisms and Cancer Risk: A Meta-Analysis","volume":"35","author":"Geng","year":"2014","journal-title":"Tumour Biol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0176","article-title":"Genetic Polymorphisms in Cytotoxic T-Lymphocyte Antigen 4 and Cancer: The Dialectical Nature of Subtle Human Immune Dysregulation","volume":"69","author":"Sun","year":"2009","journal-title":"Cancer Res"},{"key":"B171","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2020.03.017","article-title":"Association Between Immune-Related Adverse Events and Long-Term Survival Outcomes in Patients Treated With Immune Checkpoint Inhibitors","volume":"132","author":"Maillet","year":"2020","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0808284","article-title":"Genetics of Type 1A Diabetes","volume":"360","author":"Concannon","year":"2009","journal-title":"N Engl J Med"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0196-z","article-title":"Genetic Risk Analysis of a Patient With Fulminant Autoimmune Type 1 Diabetes Mellitus Secondary to Combination Ipilimumab and Nivolumab Immunotherapy","volume":"4","author":"Lowe","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B174","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jaut.2015.07.009","article-title":"Immunogenetics of Autoimmune Thyroid Diseases: A Comprehensive Review","volume":"64","author":"Lee","year":"2015","journal-title":"J Autoimmun"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.894015\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T14:50:20Z","timestamp":1676127020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.894015\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":174,"alternative-id":["10.3389\/fonc.2022.894015"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.894015","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"article-number":"894015"}}